Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, which is approximately 9.11 % above the present share price of $76.07.
Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the first quarter of 2021.
The analysts priced targets range from a high of $101 to a low of $61.
From the newest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is $99.57 billion.
According to TipRanks.com, Merrill Lynch analyst Michael Cherny is presently ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It works through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management strategies. The retail or Long Term Care segment includes offering of prescribed drugs as well as assortment of general merchandise.
The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products as well as related services, including medical, pharmacy, dental, behavioural health, healthcare management abilities. The Corporate segment involves in offering administrative services as well as management. The company was founded by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.